Bristol Myers Squibb (BMY) ended the recent trading session at $56.29, demonstrating a -0.16% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain ...

With just over 100 days as CEO now under her belt, Catherine Owen Adams is looking to cruise rare disease-focused Acadia ...

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

The talks around drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices ...

Boehringer Ingelheim’s trio of late-stage schizophrenia failures on Thursday came a day after the Department of Health and ...

The FDA has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs with a new active substance in ...

In a bumper week for new biotech financings, debutante Kardigan ruled the roost with a $300 million first round that will ...